Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>L&amp;C Bio is a high-growth player in the regenerative medicine space, with a strong focus on human tissue-based medical devices and cosmetics. The company has demonstrated a robust track record of revenue growth, driven by its flagship products like MegaDerm.</li>
 <li>Despite impressive top-line growth, the company faces significant profitability challenges, with substantial net losses and negative earnings per share reported in recent periods. This disconnect between revenue and profit is a primary concern for investors.</li>
 <li>The company is pursuing an aggressive expansion strategy, including a large-scale rights offering to fund a new global production hub in South Korea. This facility is intended to support entry into key overseas markets like the U.S. and China, which presents both a significant opportunity and a considerable execution risk.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  L&amp;C Bio is a high-growth player in the regenerative medicine space, with a strong focus on human tissue-based medical devices and cosmetics. The company has demonstrated a robust track record of revenue growth, driven by its flagship products like MegaDerm.
  Despite impressive top-line growth, the company faces significant profitability challenges, with substantial net losses and negative earnings per share reported in recent periods. This disconnect between revenue and profit is a primary concern for investors.
  The company is pursuing an aggressive expansion strategy, including a large-scale rights offering to fund a new global production hub in South Korea. This facility is intended to support entry into key overseas markets like the U.S. and China, which presents both a significant opportunity and a considerable execution risk.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: L&C Bio Co Ltd (290650 KS) - Aug 2026

Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Douglas Research Advisory

Cross Asset Strategy

<ul>
<li>There are some major surprises (both inclusions and exclusions) in the Korea Value Up index. </li>
<li>In particular, the telecom sector (SK Telecom and KT) and large cap holding companies (Samsung C&amp;T and LG Corp) are surprising exclusions in the index.</li>
<li>There are many surprising inclusions in the Korea Value Up Index. We provide 30 companies are surprising inclusions in the Korea Value Up Index (19 KOSDAQ and 11 KOSPI listed).</li>
</ul>


There are some major surprises (both inclusions and exclusions) in the Korea Value Up index. 
In particular, the telecom sector (SK Telecom and KT) and large cap holding companies (Samsung C&amp;T and LG Corp) are surprising exclusions in the index.
There are many surprising inclusions in the Korea Value Up Index. We provide 30 companies are surprising inclusions in the Korea Value Up Index (19 KOSDAQ and 11 KOSPI listed).


Korea Value Up Index - Surprising Inclusions and Exclusions

<ul>
<li>In this insight, we discuss the increasing popularity of EB issues with treasury shares as the base assets in Korea. There were seven EB issue announcements in Korea in June.</li>
<li>Going forward, more Korean companies are likely to issue EBs in the next several months, prior to the actual official changes in regulations of treasury shares in Korea.</li>
<li>These companies that issue EBs using treasury shares as underlying assets are prime targets of short selling/underperformance.</li>
</ul>


In this insight, we discuss the increasing popularity of EB issues with treasury shares as the base assets in Korea. There were seven EB issue announcements in Korea in June.
Going forward, more Korean companies are likely to issue EBs in the next several months, prior to the actual official changes in regulations of treasury shares in Korea.
These companies that issue EBs using treasury shares as underlying assets are prime targets of short selling/underperformance.


7 EB Issues in Korea in June 2025 - More Coming Until Govt Revises Treasury Shares Regulations

The Korea Exchange announced its KOSDAQ150 and KRX300 indices rebalances today. There were 17 new additions and 17 deletions for KOSDAQ150. Most of the stocks that were expected to be included in KOSDAQ 150 were officially included in the rebalance. However there were a few surprises. For example <a href="https://www.smartkarma.com/entities/nanos-co-ltd" target="_blank" data-smartkarma-citation="entities:16796:1" rel="noopener">Nanos Co Ltd (151910 KS),</a>which was one of the stocks that was expected to be included in KOSDAQ150, did not get included in this indext this time. On the other hand, the following stocks including <a href="https://www.smartkarma.com/entities/sang-a-frontec-co-ltd" target="_blank" data-smartkarma-citation="entities:20692:1" rel="noopener">Sang A Frontec (089980 KS)</a>, Novarex (194700 KS(, CIS (222080 KS), MedPacto (215980 KS), <a href="https://www.smartkarma.com/entities/koreacenter-com-co-ltd" target="_blank" data-smartkarma-citation="entities:28329:1" rel="noopener">Koreacenter.com Co Ltd (290510 KS)</a>, and Soulbrain (357780 KS) which were not on the top of the lists of getting selected into the KOSDAQ150 index by the locals, were formally selected be part of the new KOSDAQ150 inclusions.  The Korea Exchange also made changes to the KRX300 index. Although the KRX300 index is not currently as important as KOSPI200 and KOSDAQ150 indices, it is increasingly gaining in importance among the local institutional investors. The KRX300 had 33 new additions and 35 deletions.

The Korea Exchange announced its KOSDAQ150 and KRX300 indices rebalances today. There were 17 new additions and 17 deletions for KOSDAQ150. Most of the stocks that were expected to be included in KOSDAQ 150 were officially included in the rebalance. However there were a few surprises. For example Nanos Co Ltd (151910 KS),which was one of the stocks that was expected to be included in KOSDAQ150, did not get included in this indext this time. On the other hand, the following stocks including Sang A Frontec (089980 KS), Novarex (194700 KS(, CIS (222080 KS), MedPacto (215980 KS), Koreacenter.com Co Ltd (290510 KS), and Soulbrain (357780 KS) which were not on the top of the lists of getting selected into the KOSDAQ150 index by the locals, were formally selected be part of the new KOSDAQ150 inclusions.  The Korea Exchange also made changes to the KRX300 index. Although the KRX300 index is not currently as important as KOSPI200 and KOSDAQ150 indices, it is increasingly gaining in importance among the local institutional investors. The KRX300 had 33 new additions and 35 deletions. 

KOSDAQ150 and KRX300 Indices Rebalances (Overlapping Additions & Deletions)

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyzed the changes in foreign holdings of KRX stocks as of Feb 20th. The aggregated holding was USD1,264.5bn.</li>
<li>We estimate that foreign flows to be outflows of USD1,095mln. We tabulate the league table for top changes by value for 1W/4W/1Y and top stocks held by foreign institutions.</li>
<li>We highlight changes of foreign holdings in Samsung Electronics, Samsung Elec (PREF), Samsung SDI, MIRAE ASSET SEC, Hanwha Ocean.</li>
</ul>


We analyzed the changes in foreign holdings of KRX stocks as of Feb 20th. The aggregated holding was USD1,264.5bn.
We estimate that foreign flows to be outflows of USD1,095mln. We tabulate the league table for top changes by value for 1W/4W/1Y and top stocks held by foreign institutions.
We highlight changes of foreign holdings in Samsung Electronics, Samsung Elec (PREF), Samsung SDI, MIRAE ASSET SEC, Hanwha Ocean.


KRX Foreign Holding Weekly (Feb 20th): Samsung Electronics, Samsung Elec (PREF), Samsung SDI

South Korea

L&C BIO Co.,Ltd manufactures and distributes medical equipment. The Company produces equipment for nose surgery, tissue treatment, and bone regeneration. L&C BIO also produces creams, lotions, cleansers, and other cosmetics.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

L&C Bio Co Ltd (290650 KS)

Primer: L&C Bio Co Ltd (290650 KS) - Aug 2026

L&C Bio is a high-growth player in the regenerative medicine space, with a strong focus on human tissue-based medical devices and cosmetics....

αSK Primers

Korea Value Up Index - Surprising Inclusions and Exclusions

There are many surprising inclusions and exclusions in the Korea Value Up Index. We provide 30 companies that are surprising inclusions and 10...

Douglas Kim

7 EB Issues in Korea in June 2025 - More Coming Until Govt Revises Treasury Shares Regulations

EB issues with treasury shares as the base assets in Korea have been becoming more popular in Korea in recent weeks. These companies that issue EBs...

Douglas Kim

KOSDAQ150 and KRX300 Indices Rebalances (Overlapping Additions & Deletions)

We highlight the KOSDAQ150 and KRX300 indices rebalances. There are some interesting new names, especially among those that are over lapping in...

Douglas Kim

KRX Foreign Holding Weekly (Feb 20th): Samsung Electronics, Samsung Elec (PREF), Samsung SDI

We analyzed KRX foreign holding data for the past week and highlighted foreign holding changes in Samsung Electronics, Samsung Elec (PREF), Samsung...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)